Know Cancer

or
forgot password

Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer


Inclusion Criteria:



- locally advanced or metastatic adenocarcinoma of the pancreas

- no prior chemotherapy

- performance status 0-2

- adequate hematology and chemistry

Exclusion Criteria:

- serious concurrent medical condition

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

time to tumor progression

Principal Investigator

Ron Epelbaum, MD

Investigator Role:

Principal Investigator

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

RonCurcuminPancreas.CTIL

NCT ID:

NCT00192842

Start Date:

July 2004

Completion Date:

September 2010

Related Keywords:

  • Pancreatic Cancer
  • carcinoma
  • pancreas
  • gemcitabine
  • curcumin
  • Pancreatic Neoplasms

Name

Location